Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.

The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).

-Baseline and Cycle 2 Day 1

"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."